NCT05292040

CompletedPhase 1

A Study of LY3857210 in Healthy Participants

Eli Lilly and Company Source

Eli Lilly and Company

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

18313

Secondary identifiers

J3O-MC-LSBA

OTHER · Eli Lilly and Company

Study Type

interventional

Actual enrollment (reported)

10

Locations

1 country

Sites

1

Timeline

Study Start

March 17, 2022

Actual (reported)

Primary Completion

December 14, 2022

Actual (reported)

Study Completion

December 14, 2022

Actual (reported)

Brief Summary

The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand \[18F\]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to approximately 6 weeks for each participant and may include up to four visits to the study center.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 10 participants
Study completion date: December 14, 2022
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
March 14, 2022
Actual (reported)
Study Start
March 17, 2022
Actual (reported)
First Posted
March 23, 2022
Actual (reported)
Primary Completion
December 14, 2022
Actual (reported)
Study Completion
December 14, 2022
Actual (reported)

Last Updated: March 1, 2023
Status Verified: February 2023
Last Update Submitted: February 28, 2023

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

Change from baseline in brain receptor occupancy (RO) of LY3857210 measured by [18F]-LY3818850 PET scan
Change from baseline in brain RO of LY3857210 measured by \[18F\]-LY3818850 PET scan
Baseline through study completion, up to approximately 6 weeks

Study Arms (1)

LY3857210

EXPERIMENTAL

Single doses of LY3857210 administered orally.

Drug: LY3857210

Interventions

LY3857210Drug

Administered orally.

LY3857210

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Overtly healthy male or female participants as determined by medical evaluation
Have body weight ≥ 45 kilograms (kg) and body mass index (BMI) within the range 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive)

Sponsors & Collaborators

Eli Lilly and Company
Industrylead

Study Sites (1)

Invicro, Institute for Neurodegenerative Disorders

New Haven, Connecticut, 06510, United States

Study Officials

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
STUDY DIRECTOR

Enrollment

10 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: BASIC SCIENCE
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 14, 2022

First Posted

March 23, 2022

Study Start

March 17, 2022

Actual (reported)

NCT05509816

A Study of Imlunestrant (LY3484356) in Healthy Women

Phase 1Completed

NCT05038787

A Study of LY3473329 in Healthy Japanese Participants

Phase 1Completed

NCT05602675

A Drug Interaction Study of LY3871801 in Healthy Participants

Phase 1Completed

NCT05567159

A Study of Donanemab (LY3002813) in Healthy Participants

Phase 1Completed

NCT05069896

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

Phase 1Completed

NCT04991766

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

Phase 1Completed

Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential

You may not qualify if:

Have contraindications to undergoing magnetic resonance imaging (MRI) examination including but not limited to implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips, and other medical implants that have not been certified for head MRI
Have clinically significant findings on the screening MRI scan, as judged by the investigator
Suffer from claustrophobia and would be unable to tolerate the confined spaces of MRI or PET camera

Contact the study team to confirm eligibility.

Primary Completion

December 14, 2022

Actual (reported)

Study Completion

December 14, 2022

Actual (reported)

Last Updated

March 1, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT05292040
Data provider: ClinicalTrials.gov
Source updated: 2023-03-01
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:23:32 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

LY3857210

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations